Themis Medicare Ltd
Themis Medicare Q2 FY25 earnings call: Revenue & Margins
Q2 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹117Cr
- +11.7% YoY
- Net profit
- ₹14Cr
- +26.2% YoY
- Margin
- 14.64%
- +2.8 pp YoY
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Themis Medicare Ltd Q2 FY25 key numbers
- Revenue
- Q2 FY25 Net Revenue: Rs. 117.01 Cr, up 11.67% YoY from Rs. 104.78 Cr in Q2 FY24.
As stated in Themis Medicare Ltd's Q2 FY25 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on Themis Medicare Ltd's Q2 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY25 Net Revenue: Rs. 117.01 Cr, up 11.67% YoY from Rs. 104.78 Cr in Q2 FY24 (Page 8). Q2 FY25 Financials:.
From Themis Medicare Ltd's Q2 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q2 FY25 Net Revenue: Rs. 117.01 Cr, up 11.67% YoY from Rs. 104.78 Cr in Q2 FY24 (Page 8).
- H1 FY25 Net Revenue: Rs. 240.00 Cr, up 19.15% YoY from Rs. 201.43 Cr in H1 FY24 (Page 9).
- Formulation Segment grew >36% YoY in Q2 FY25 (Page 8).
- Hospital Business grew over 13% YoY in Q2 FY25 (Page 6, 8).
- Trade Business grew over 45% YoY in Q2 FY25 (Page 6, 8).
- Incremental sales from higher-realization products and productivity focus contributed to margin improvement despite API pricing pressures (Page 8).
2 more points from Themis Medicare Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Themis Medicare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Themis Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Themis Medicare Ltd said on order book & pipeline — free account, 30 seconds.
Themis Medicare Ltd — Quarterly revenue & net profit
Themis Medicare Ltd Q2 FY25 results — key figures
| ₹ Cr | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 117 | 105 | +11.7% | 123 | -4.9% |
| Operating profit (EBITDA) | 17 | 12 | +38% | 29 | -41.3% |
| Operating margin | 14.64% | 11.84% | +2.8 pp | 23.73% | -9.1 pp |
| Profit before tax | 18 | 14 | +27.5% | 31 | -43.2% |
| Net profit (PAT) | 14 | 11 | +26.2% | 25 | -42.1% |
| EPS (₹) | 1.55 | 1.23 | +26% | 2.68 | -42.2% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹77 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Themis Medicare's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
- Jubilant Pharmo (Q2 FY25)
Q2’FY25 total income grew 5% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
- Wockhardt (Q2 FY25)
Q1 FY25 total income reported at INR 747 Cr., a 14% growth year-on-year versus Q1 FY24 income of INR 658 Cr. Key concall takeaways from Wockhardt Ltd's Q2 FY25…
- Anuh Pharma (Q2 FY25)
Q2 FY25 Revenue: Rs 169.35 Cr (Page 6) . Key concall takeaways from Anuh Pharma Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Themis Medicare Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Themis Medicare Ltd Q2 FY25 results?
Q2 FY25 Net Revenue: Rs. 117.01 Cr, up 11.67% YoY from Rs. 104.78 Cr in Q2 FY24 (Page 8). Q2 FY25 Financials:.
What is Themis Medicare Ltd share price analysis?
Themis Medicare Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,142 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Themis Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.